Program
HL-300
A development code.
Its studies are mostly in Dermatitis, Atopic, led by Hangzhou Highlightll Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hangzhou Highlightll Pharmaceutical | 21 open or running | phase 2since Jun 1, 2026 | Jun 1, 2026 | Jun 30, 2027phase 2 · NCT07629778 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 1, 2026First study: phase 1 study in Dermatitis, AtopicFirst studyNCT07684937 · 36 enrolled
- Jun 1, 2026Phase 2 study in Dermatitis, AtopicNCT07629778 · 156 planned · China
Ahead
- Jun 30, 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT07629778
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07684937Dermatitis, Atopic | 1 | Completed | Nov 25, 2024 | 36 |
| NCT07629778Dermatitis, Atopic · China | 2 | Recruiting | Jun 30, 2027 | 156 |
How it is read
Names in the registry
- “HL-300”, 7 entries
Codes read as this program: HL300.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.